TCRX — TScan Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1783328 ·
Last close
$0.74
Market Cap
$45.38M
52W High
$1.34
52W Low
$0.73
ADV30
840,620
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 982,000 | — | -29,139,000 | -28,666,000 | 201,991,000 | 128,057,000 | 105,069,000 |
| Dec 2025 | 2,567,000 | — | -23,858,000 | -22,977,000 | 228,789,000 | 152,406,000 | 105,666,000 |
| Sep 2025 | 2,511,000 | — | -37,052,000 | -35,710,000 | 262,225,000 | 169,506,000 | 118,204,000 |
| Jun 2025 | 3,076,000 | — | -38,653,000 | -36,952,000 | 298,561,000 | 169,394,000 | 121,847,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-135,319,000
Investing CF
$109,372,000
Financing CF
$-336,000
CapEx
$-4,407,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-1.00
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-504,862,000
Inventory
—
Receivables
—
ST Investments
$0
EBIT TTM
$-126,997,000
Pretax Income TTM
$-129,766,000
Interest Exp TTM
$2,769,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$9,136,000
EBITDA
$-123,821,000
Free Cash Flow
$-84,107,624
Enterprise Value
$13,035,657
Total Cash
$128,057,000
Total Debt
$92,537,000
Shares Out
61,074,229
Trailing EPS
$-0.96
Book Value
$1.61
ROE
-80.9%
ROA
-29.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 10,325,000 | -135,813,000 | -129,766,000 | 228,789,000 | 105,666,000 | — | -135,319,000 |
| Dec 2024 | 2,816,000 | -134,821,000 | -127,499,000 | 371,118,000 | 130,148,000 | — | -110,822,000 |
| Dec 2023 | 21,049,000 | -93,458,000 | -89,218,000 | 272,149,000 | 121,282,000 | — | -61,358,000 |
| Dec 2022 | 13,535,000 | -66,636,000 | -66,221,000 | 199,091,000 | 99,657,000 | — | -66,503,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.89
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MGX | Metagenomi Therapeutics, Inc. | $44.80M | $1.19 | — |
| INMB | Inmune Bio, Inc. | $46.52M | $1.75 | — |
| SCLX | Scilex Holding Co | $46.87M | $6.66 | — |
| ATYR | aTYR PHARMA INC | $47.65M | $0.49 | — |
| EXOZ | EXOZYMES INC. | $43.16M | $4.65 | — |
News headlines (Yahoo Finance, 1h cache)
Cell and gene therapy manufacturers turn to specialist automation partners
2026-07-31 10:17 · Yahoo
TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies
2026-07-29 11:00 · Yahoo
TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
2026-06-24 11:00 · Yahoo
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transpl
2026-06-22 11:00 · Yahoo
TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss
2026-06-02 13:57 · Yahoo
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates
2026-05-06 12:25 · Yahoo
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-06 11:00 · Yahoo
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting
2026-04-27 20:30 · Yahoo
TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
2026-04-08 11:00 · Yahoo
Strong Analyst Sentiment on TScan Therapeutics (TCRX) Amid Ongoing Momentum in Cell Therapy Space
2026-03-25 19:35 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.